Delcath Systems (DCTH) Announces First European Chemosat Procedures for Treatment of Cancers in Liver
Delcath Systems Inc., a development-stage specialty pharmaceutical and medical device company focused on oncology, today announced that the first patients in Europe have been treated with the Delcath Hepatic CHEMOSAT® Delivery System at the European Institute of Oncology (IEO), a premier cancer treatment and research center in Milan. CHEMOSAT is a proprietary product that utilizes a minimally invasive, repeatable procedure to deliver high doses of chemotherapeutic drugs directly to the liver while minimizing systemic exposure of such drugs. The two patients were treated for inoperable liver-dominant metastases from ocular melanoma and gastric cancer. Delcath reports that the procedures were successfully…